Moors & Cabot Inc. Sells 355 Shares of Sanofi (NASDAQ:SNY)

Moors & Cabot Inc. trimmed its stake in shares of Sanofi (NASDAQ:SNY) by 4.5% in the fourth quarter, HoldingsChannel reports. The firm owned 7,480 shares of the company’s stock after selling 355 shares during the quarter. Moors & Cabot Inc.’s holdings in Sanofi were worth $361,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of SNY. Synergy Asset Management LLC acquired a new stake in shares of Sanofi during the 4th quarter worth about $25,000. McClarren Financial Advisors Inc. raised its holdings in Sanofi by 952.6% in the 4th quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after acquiring an additional 543 shares during the period. Sunbelt Securities Inc. lifted its position in Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock worth $43,000 after acquiring an additional 313 shares during the last quarter. Sierra Ocean LLC bought a new stake in shares of Sanofi during the fourth quarter worth approximately $44,000. Finally, Versant Capital Management Inc acquired a new position in shares of Sanofi in the fourth quarter valued at approximately $54,000. 14.04% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

SNY has been the subject of several research reports. StockNews.com cut Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Deutsche Bank Aktiengesellschaft raised Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Finally, Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a research report on Thursday, January 30th. Two research analysts have rated the stock with a hold rating, one has assigned a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat.com, Sanofi has a consensus rating of “Buy” and an average target price of $60.00.

Sanofi Price Performance

Sanofi stock opened at $57.75 on Friday. The firm has a market cap of $146.56 billion, a PE ratio of 23.19, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. The company has a debt-to-equity ratio of 0.15, a current ratio of 1.46 and a quick ratio of 1.14. The stock’s fifty day moving average price is $53.65 and its two-hundred day moving average price is $52.83. Sanofi has a one year low of $45.22 and a one year high of $60.12.

Sanofi (NASDAQ:SNY) last issued its quarterly earnings results on Thursday, January 30th. The company reported $0.70 EPS for the quarter, hitting analysts’ consensus estimates of $0.70. Sanofi had a return on equity of 25.61% and a net margin of 12.77%. As a group, research analysts expect that Sanofi will post 4.36 EPS for the current fiscal year.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.